A new initiative to increase hepatitis B virus vaccination rates among at-risk adults has been developed.
The FDA has granted Fast Track designation to a novel antiviral in development for the treatment of HBV infection.
Vemlidy, a nucleoside analogue (reverse transcriptase inhibitor), is currently approved to treat chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.
For the analysis, study authors looked at data specifically for patients with type 2 diabetes aged 60 to 70 years.
Patients with rheumatoid arthritis with chronic hepatitis B virus infection demonstrated greater radiographic progression and poorer clinical response at 1 year.
The authors examined data from 8887 individuals who began TNF antagonist treatment for an autoimmune disease from 2001 through 2010 and were followed through 2012; 52% of these patients were screened for HBV before treatment.
Findings highlight the importance of screening for metabolic syndrome (MS) and the potential for MS to influence alanine aminotransferase and its interpretation in the context of HBV treatment decisions.
Maternal use of tenofovir disoproxil fumarate does not lower hepatitis B virus transmission rates.
For patients with chronic HBV, BMI is significantly associated with increased risk of hepatocellular carcinoma.
Hepatitis B e-antigen positive mothers receiving tenofovir daily from 28-weeks gestation to 2 months postpartum did not show significant reductions in HBV transmission rates compared to placebo treated participants.
The FDA approval of Heplisav-B was based on data from 3 phase 3 noninferiority trials involving close to 10,000 adults who received the vaccine.
The Advisory Committee on Immunization Practices has issued updated recommendations for HBV prevention.
Dynavax Technologies announced the availability of a two-dose hepatitis B vaccine for adults.
More than one-third of adult US HIV patients miss opportunities to initiate hepatitis B vaccination.
Hepatitis B and hepatitis C may increase mortality risks in patients with HIV.
The combined presence of alcohol abuse, HBV, and HCV generates an additive effect on the risk of cirrhosis in women than in men.
High aspartate aminotransferase levels completely mediated the effects of HBV infection on any cataract.
Elevated levels of hepatitis B virus DNA and hepatitis B surface antigen are associated with increased risks of liver cancer.
Screening, vaccination, and linkage to care will reduce the high costs associated with hepatitis B infection.
Although it is commonly accepted that lamivudine prophylaxis should be started a few weeks before chemotherapy is administered, the best time for lamivudine discontinuation is still controversial.
The FDA approves new hepatitis B virus vaccine for adults.
Patients who take aspirin may significantly reduce their risk of hepatitis B-related hepatocellular carcinoma.
Despite continual efforts aimed at finding new treatment options, HCC still has a very low 5-year survival rate, less than 20%, as many patients are diagnosed at an advanced stage of the disease.
Hepatitis B virus reactivation rates differ in patients with inflammatory arthritis.
HIV, hepatitis B, and hepatitis C infections are more prevalent among patients with severe mental illness than in the general population.
The first dose of the hepatitis B vaccine should be given within the first 24 hours of life.
One of the main challenges in managing and controlling hepatitis B infection today is identifying people who are infected and ensuring that they have access to suitable treatment.
The World Health Organization published a position paper with updated recommendations on the use of the hepatitis B vaccine regarding target groups, immunization schedules, and storage and distribution.
For patients with chronic hepatitis B, achievement of subcirrhotic range of liver stiffness with antiviral therapy is linked to lower risk of hepatocellular carcinoma.
A study showed that telbivudine administered during early and middle pregnancy prevented transmission of hepatitis B virus infection from mother to infants in all participants receiving antiviral treatment.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Isavuconazole Not Noninferior to Caspofungin for Invasive Candida Infections
- Three New Ebola Vaccines Demonstrate Persistent Immune Response
- Dundee Severity Classification Improves Management of Patients With Cellulitis
- Pregnant Women Commonly Refuse Vaccines
- Tap Water in Neti Pot Linked to Death From Brain-Eating Amoeba
- Prenatal Malaria Exposure Modulates Innate Immune Responses at Birth
- Best Approach to Reduce Surgical Site Infections Before Colorectal Surgery
- A Single Triple-Drug Treatment for Lymphatic Filariasis
- Cyclosporiasis Cases Markedly Higher in 2018 Than Previous 2 Years
- Mail-Based HPV Testing May Increase Access